Fasen­ra shows pos­i­tive PhI­II topline da­ta for nasal polyps, tight­en­ing race with GSK's Nu­cala

The high­ly con­test­ed res­pi­ra­to­ry field just got even tighter Thurs­day.

As­traZeneca re­vealed topline da­ta for a Phase III tri­al Thurs­day eval­u­at­ing its Fasen­ra asth­ma ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER